1 **The life expectancy of chronic myeloid leukemia patients is approaching the**

2 **life expectancy of the general population**

3 Hannah Bower[1], Magnus Björkholm[2], Paul W. Dickman[1], Martin Höglund[3], Paul C.

4 Lambert[1,4] and Therese M.-L. Andersson[1,5]

5 [1]Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,

6 Stockholm, Sweden

7 [2]Department of Medicine, Division of Hematology, Karolinska University Hospital

8 Solna and Karolinska Institutet, Stockholm, Sweden

9 [3] Department of Medical sciences (Hematology), University Hospital Uppsala,

10 Uppsala, Sweden

11 [4] Department of Health Sciences, University of Leicester, Leicester, UK

12 [5] Danish Cancer Society, Documentation and Quality, Copenhagen, Denmark

17 **Corresponding author:** Hannah Bower, Department of Medical Epidemiology and

18 Biostatistics, Karolinska Institutet, 171 77 Stockholm, Sweden; email:

19 hannah.bower@ki.se

20 **Running head:** Life expectancy of CML patients approaching that of population

24 **Conflict of interest:** The authors declare no competing financial interests.

Abstract

PURPOSE A dramatic improvement in the survival of chronic myeloid leukemia (CML) patients occurred after the introduction of imatinib myeselate (IM), the first tyrosine kinase inhibitor (TKI). We assess how these changes affect the life expectancy of CML patients and life years lost due to a diagnosis of CML between 1973 and 2013 in Sweden.

MATERIALS AND METHODS Patients recorded as having CML in the Swedish Cancer registry from 1973 to 2013 were included in the study and followed until death, censoring or end of follow-up. The life expectancy and loss in expectation of life were predicted from a flexible parametric relative survival model.

RESULTS 2,662 CML patients were diagnosed between 1973 and 2013. Vast improvements in the life expectancy of CML patients were seen over the study period; larger improvements were seen in the youngest ages. The great improvements in life expectancy translated into great reductions in the loss in expectation of life. Patients of all ages diagnosed in 2013 will on average lose less than 3 life years due to their diagnosis of CML.

CONCLUSION Imatinib mesylate, new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in CML patients approaching that in the general population today. This will be a very important message to convey to patients in order to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of CML patients will have a great effect on future healthcare costs as long as continuous TKI treatment is required.

Introduction

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by an acquired balanced chromosomal translocation, giving rise to a constitutively active tyrosine kinase (BCR–ABL1) [1]. Untreated or symptomatically treated CML is a fatal disease, with a reported median survival of approximately 2–3 years in seemingly unselected CML populations [4]. Over 90% of Swedish patients are diagnosed in the chronic phase, and the major treatment goal is to prevent the disease from progressing into more advanced phases [3]. Treatment for CML patients has changed dramatically over the years. CML therapy was restricted to busulphan and hydroxyurea prior to the 1980s [4]. During the 1980s allogeneic stem cell transplantations (allo-SCT) and interferon-α were the treatments of choice. [6]. A dramatic improvement occurred after 2000 due to the introduction of imatinib mesylate (IM), the first tyrosine kinase inhibitor (TKI) specifically targeting the BCR–ABL1 oncoprotein [1]. IM treatment significantly increased the survival and quality of life for patients of all ages, particularly for patients in chronic phase [7,8].

The improved survival has led to an increasing prevalence, a trend that is projected to continue during coming decades[2,3,9]. The increased prevalence in combination with, for the large majority of patients, the recommended life-long IM treatment will have a great impact on costs [9]. It will be very important to, in an accessible way, guide health care professionals, educators, and policy makers regarding present and future achievements with a focus on population-based data. It is also important for these groups, as well as for patients and clinicians, that survival statistics are presented in a comprehendible way, that enhance the understanding of the impact of a cancer diagnosis on a patient's life expectancy, especially for chronic diseases such as CML.

74   Life expectancy is a simple, well-known concept that quantifies the expected number

75   of life years remaining. The loss in expectation of life (LEL) is a survival measure that

76   presents the number of life years lost, or the reduction in the life expectancy, due to a

77   diagnosis of cancer [13,14]. These measures have many advantages including being

78   easily comprehendible, and thus easily communicated, and providing a survival

79   measure over a whole time scale.

80   The aim of this study is to assess how the life expectancy of CML patients and life

81   years lost due to a diagnosis of CML have changed between 1973 and 2013 in

82   patients diagnosed in Sweden. Particular interest lies in the survival of patients after

83   the introduction of the TKIs. An additional aim is to determine whether improvements

84   previously reported in the survival of CML patients in Sweden have continued

85   between 2008 and 2013.

Methods

Cancer registries and patients

The study included CML patients recorded within the nationwide Swedish Cancer Registry established in 1958. By law every incidence of cancer must be reported to this registry by each physician and pathologist/cytologist. The Swedish Cancer registry contains information on age, sex, date and type of diagnosis but does not contain detailed information such as symptoms, routine laboratory tests, treatments and comorbidities [15]. Patients with CML were identified using International Classification Version 8 (code 2051). All residents in Sweden are given a unique national registration number which was used for linkage with the national Cause of Death Register to obtain the date of death.

Patients who were diagnosed between January 1, 1973 and December 31, 2013 were included within the cohort. Patients were followed until their date of death, date of emigration or to the end of follow-up (31 December 2013), whichever occurred first. Diagnoses were included from 1973 since the registry is known to have reached a high coverage for hematological malignancies by then [16]. Only the first diagnosis of CML of patients diagnosed at 50 years of age or above which were histologically verified were considered. The reason for including patients aged 50 years and above at diagnosis was so that long extrapolation was not required when calculating the loss in expectation of life. Incidental autopsy findings and misclassified cases were excluded. The study was approved by the Stockholm Regional Ethics Review Board. Informed consent was waived since there was no contact with study participants.

108 *Statistical methods*

109 The loss in expectation of life (LEL) is the difference between the life expectancy of a

110 cancer patient and the life expectancy of a similar individual, in terms of age and sex,

111 from the general population. This measure estimates the average number of life

112 years lost, or the reduction in the life expectancy, due to a diagnosis of cancer. The

113 LEL can also be presented as a proportion, in the form of the proportion of expected

114 life lost (PELL). This is the proportion of remaining life years that are lost due to a

115 diagnosis of cancer. The LEL and PELL can be estimated based on the relative

116 survival of the cancer patients and the survival of the general population [13]. Relative

117 survival is defined as the all-cause observed survival in the cancer population under

118 study divided by the expected survival of a comparable group in the general

119 population [17,18].

120 The LEL and PELL were predicted from a flexible parametric relative survival model

121 with 5 degrees of freedom to model the baseline excess hazard [19,20]. Age at

122 diagnosis, year of diagnosis and sex were all modeled (age and year continuously

123 using restricted cubic splines [21]) and interactions between all these covariates were

124 included. The model included time-dependent effects with 2 degrees of freedom for

125 all covariates to allow for non-proportional excess hazards. The expected survival

126 was obtained from population mortality files up to 2012 and predictions beyond 2012

127 by Statistics Sweden [22] stratified on age at diagnosis, year of diagnosis and sex.

128 All analyses were performed in Stata 13 [23].

129

Results

A total of 2,662 CML patients diagnosed between 1973 and 2013 at age 50 years
and over, 1,446 (54.3%) males and 1,216 (45.7%) females were included. The
median age at diagnosis for the included cohort was 69 years. See Table 1 for
descriptive statistics.

Results are presented for four selected ages at diagnosis; 55, 65, 75 and 85 years.
The life expectancy of the general population for males and females increased over
the follow-up period; this increase was larger for the younger populations presented.
The life expectancy of the CML patients steadily increased for all ages between 1973
and 1990. For younger CML patients presented in this study, a large increase in the
life expectancy was seen after 1990, this increase was not as great in the older
patients and began later, see Figure 1. The increase seen in the life expectancy in
those aged 55 at diagnosis after 1990 continued until 2013; however the largest
increase was seen between approximately 1990 and 2000, with a more steady
increase after 2000. In those CML patients aged 85 years at diagnosis the greatest
increase in life expectancy began from approximately 2000. The life expectancy of
CML patients of all ages increased dramatically over the whole of the study period
which resulted in the life expectancy of CML patients in 2013 was approaching that in
the general population. For example, a 55-year old male CML patient diagnosed in
1980 would on average have 3.5 (95% CI: 2.9, 4.1) life years remaining whereas a
55-year old male diagnosed in 2010 would have 27.3 (95% CI: 25.7, 28.8) life years
remaining. An 85-year old male patient would on average have 0.8 (95% CI: 0.7, 1.1)
life years remaining if he was diagnosed in 1980 and 4.1 (95% CI: 3.4, 4.7) life years
remaining if he was diagnosed in 2010. The life expectancy of all aged CML patients

154 was within 3 years of the life expectancy in the general population for diagnoses in

155 2010, as shown in the LEL estimates; see Table 2 and Figure 2.

156 The LEL decreased for all ages over the study period but the most dramatic decrease

157 was seen in diagnoses after 1990 in younger patients presented. This was due to the

158 huge increase in the life expectancy of CML patients at this time; see Figure 2 and

159 Table 2. For example, a male diagnosed with CML in 1980 at age 55 on average had

160 a reduced life expectancy of 20.8 (95% CI: 20.2, 21.4). In contrast, a 55-year old

161 male diagnosed in 2010 would on average have a reduced life expectancy of only 2.6

162 (95% CI: 1.0, 4.1) years For older patients, improvements were still seen, with a more

163 rapid decrease after the 1990s, but not to the same scale as in the younger patients

164 since older patients have on average fewer potential remaining life years.

165 Estimates of PELL also suggest a vast improvement in the outcomes of CML patients

166 of all ages over the study period; see Figure 3 and Table 2. Prior to approximately

167 1990, the PELL was higher in younger patients included in the study, whereas after

168 this time the PELL was higher in the older patients. For example, the PELL for a 55-

169 year old male and an 85-year old male diagnosed in 1980 were 86% (95% CI: 83%,

170 88%) and 80% (95% CI: 76%, 85%) respectively, in 2010 these values were 9%

171 (95% CI: 4%, 14%) and 28% (95% CI: 16%, 40%) respectively.

172

Discussion

Our results show that there has been a dramatic reduction in the life years lost in patients diagnosed in Sweden with CML between 1973 and 2013. Patients aged 55 years at diagnosis benefitted greatly from 1990, and life expectancy improvements continued to 2013 but less dramatically from 2000. For older patients, improvements in life expectancy began a little later. The results indicate that the life expectancy of CML patients is now close to the life expectancy of the general population for all ages[10-12]. However, reports suggesting an increased incidence of other cancers [10,11] and cardiovascular morbidity [12] associated with the use of TKIs, could have a negative impact on survival gains. Thus the life expectancy of CML patients may never reach that seen in the general population. Also, approximately 10% of CML patients diagnosed in Sweden are diagnosed in an advanced phase, and it is therefore unlikely that the life expectancy for the whole group of CML patients will reach the life expectancy of the whole population. Even so, the life expectancy of CML patients was within 3 years of the life expectancy in the general population for diagnoses in 2010, which must be seen as a great success of CML treatment.

Treatment for CML patients has changed dramatically over the years, and IM was approved as CML treatment in Sweden in 2001 (second line) and 2002 (first line). However, the implementation of imatinib differed between age groups: during the period 2002–2008 it was on average 79% in persons below 70 years and 47% in persons older than 70 years, leading to a less conspicuous or no improvement in survival for elderly patients [2]. These proportions increased to 94% for younger (<70 years) and 79% for older (>80 years) patients during 2007-2009 [3]. Although IM remains the gold standard for first-line treatment of CML, the appearance of IM resistance and intolerance has led to the development of several additional TKIs [24].

198 Studies have shown that second-generation TKIs (dasatinib, nilotinib, bosutinib)

199 improve outcome of CML patients in whom IM therapy has failed [24,25]. In addition, a

200 third-generation TKI (ponatinib) targeting the frequently observed mutant T315I has

201 been developed [26]. Thus, CML treatment is progressing rapidly and further

202 advancements are anticipated. Notwithstanding the fact that a small subgroup of

203 patients with an excellent response to treatment have been able to stop taking TKI

204 agents [27], most CML patients will take the drug for life which, along with the

205 increasing prevalence of CML, has high implications for the cost. Ohm et al.

206 evaluated the cost-effectiveness of IM in CML patients and found that incremental

207 cost-effectiveness ratios comparing IM to other treatments were generally acceptable

208 by health authorities [9] meaning that these treatments should continue to be

209 financially feasible.

210 The results shown for the youngest patients presented here suggest that

211 improvements in survival of CML patients began for patients diagnosed in the mid-

212 1990s. Our results also show improvements from the introduction of IM in 2001,

213 however, great improvements are observed prior to its introduction. The

214 improvements seen for older patients began slightly later than the younger patients

215 presented; however there was no immediate improvement after 2001 when IM was

216 introduced. The use of interferon-α[28], more precise diagnostics involving centralised

217 cytogeneic labs and a more structured approach in treating and monitoring CML

218 patients are plausible explanations for the trend.. Although our research suggests

219 that improvements in survival of CML patients over the years may not have been

220 completely due to the introduction of IM, it is clear that the prognosis for CML patients

221 today is extremely positive with the current treatment.

222 Sasaki et al. concluded from clinical trial data that the five-year survival of chronic-

223 CML patients was almost the same as the general population[29]; our results support

224 this finding. Björkholm et al. followed Swedish CML patients on a population level and

225 saw improvements in the relative survival between 1973 and 2008 for Swedish CML

226 patients of all ages, with vast improvements in those aged 79 years and less at

227 diagnosis from 2001 [2]. Our study shows that these improvements have continued to

228 2013. We here chose to present outcomes in CML patients using LEL whilst others

229 quantified survival using relative survival. It is important to remember that these two

230 measures are related but describe different aspects of the patients' survival. In

231 particular, the relative survival is an estimate of net survival which is interpreted in a

232 hypothetical situation where cancer patients can only die of their cancer whereas the

233 loss in expectation of life is a measure which represents the real-world survival seen

234 by cancer patients.

235 One potential limitation of the study is that the current analysis is not able to capture

236 any late lethal effects if they were to occur, due to fewer years of follow-up in the later

237 calendar years; the fewer years of follow-up also mean that the estimates presented

238 rely more on the model assumptions. However, it is also possible that any late

239 adverse effects may not impact the life span of patients.

240 A major strength of the current study is the use of population-based information; we

241 include all CML diagnoses reported to the Swedish Cancer Register between 1973

242 and 2013. The Swedish Cancer Register has high completeness; in 1998 it was

243 estimated to capture 96% of all cancers in Sweden [16]. Using population-based data is

244 optimal since it captures the mortality of CML patients in Sweden on a whole whilst

245 incorporating changes in treatments, increasing prevalence of CML and potential

246 negative side-effects of treatments for CML patients. Unfortunately, the Swedish

247   Cancer Register doesn't contain information on treatment and other detailed clinical

248   information. This also means that there is a lack of potential confounder information

249   such as socioeconomic status.

250   In order to present the LEL for all patients including those diagnosed in the most

251   recent years, extrapolation from models are required. This potential weakness of the

252   LEL has been assessed by Andersson et al.[13] in several different cancers and

253   extrapolation was shown to be accurate. However, further extrapolation is required to

254   calculate the LEL in younger patients due to their larger potential life expectancy.

255   Therefore, the LEL was presented for patients aged 55 years and above.

256   In conclusion, the life expectancy, and the number of life years lost, has vastly

257   improved in all-aged CML patients in Sweden since 1973 with larger improvements

258   beginning already in the mid-1990s. IM along allo-SCT and other factors have

259   contributed to the life expectancy in CML patients being almost the same as the

260   general population today.

261

262

References

1.	Druker BJ: Current treatment approaches for chronic myelogenous leukemia. Cancer Journal 7:S14-S18, 2001

2.	Bjorkholm M, Ohm L, Eloranta S, et al: Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. Journal of Clinical Oncology 29:2514-2520, 2011

3.	Hoglund M, Sandin F, Hellstrom K, et al: Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 122:1284-1292, 2013

4.	Wedelin C, Bjorkholm M, Mellstedt H, et al: Clinical findings and prognostic factors in chronic myeloid leukemias. Acta Med Scand 220:255-60, 1986

5.	Goldman JM: Allogeneic bone marrow transplantation: state of the art and future directions. Bone Marrow Transplant 4 Suppl 1:133-4, 1989

6.	O'Brien S, Kantarjian H, Talpaz M: Practical guidelines for the management of chronic myelogenous leukemia with interferon alpha. Leuk Lymphoma 23:247-52, 1996

7.	Druker BJ, Sawyers CL, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-42, 2001

8.	O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003

9.	Ohm L, Lundqvist A, Dickman P, et al: Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib. Leukemia & Lymphoma 56:1385-1391, 2015

10.	Duman BB, Paydas S, Disel U, et al: Secondary malignancy after imatinib therapy: eight cases and review of the literature. Leukemia & Lymphoma 53:1706-1708, 2012

11.	Gunnarsson N, Stenke L, Hoglund M, et al: Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. British Journal of Haematology 169:683-688, 2015

12.	Dahlen T, Edgren G, Hoglund M, et al: Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries. Blood 124, 2014

13.	Andersson TML, Dickman PW, Eloranta S, et al: Estimating the loss in expectation of life due to cancer using flexible parametric survival models. Statistics in Medicine 32:5286-5300, 2013

14.	Hakama M, Hakulinen T: Estimating the expectation of life in cancer survival studies with incomplete follow-up information. J Chronic Dis 30:585-97, 1977

15.	Socialstyrelsen: Cancer incidence in Sweden 2011.,

16.	Barlow L, Westergren K, Holmberg L, et al: The completeness of the Swedish Cancer Register - a sample survey for year 1998. Acta Oncologica 48:27-33, 2009

17.	Dickman PW, Adami HO: Interpreting trends in cancer patient survival. Journal of Internal Medicine 260:103-117, 2006

18.	Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6:101-21, 1961

19.	Lambert PC, Royston P: Further development of flexible parametric models for survival analysis. Stata Journal 9:265-290, 2009

20.	Lambert PC, Royston P: Flexible Parametric Survival Analysis Using Stata: Beyond the Cox model, Stata Press, 2011

21.	Durrleman S, Simon R: Flexible Regression-Models with Cubic-Splines. Statistics in Medicine 8:551-561, 1989

22.   Statistics Sweden: The future population of Sweden 2012-2060, Demographics report 2012

23.   StataCorp: Stata Statistical Software: Release 13. College Station, TX, StataCorp LP, 2013

24.   Jabbour E, Kantarjian H, Cortes J: Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm. Clinical Lymphoma Myeloma & Leukemia 15:323-334, 2015

25.   Ibrahim AR, Clark RE, Holyoake TL, et al: Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica-the Hematology Journal 96:1779-1782, 2011

26.   Cortes JE, Kim DW, Pinilla-Ibarz J, et al: A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias. New England Journal of Medicine 369:1783-1796, 2013

27.   Mahon FX, Rea D, Guilhot J, et al: Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology 11:1029-1035, 2010

28.   Kantarjian HM, Smith TL, Obrien S, et al: Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon-Alpha Therapy. Annals of Internal Medicine 122:254-261, 1995

29.   Sasaki K, Strom SS, O'Brien S, et al: Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematology 2:E186-E193, 2015

263 **Figure legends**

264 **Figure 1:** Life expectancy of the general population and of CML patients in Sweden,

265 over year of diagnosis, by age at diagnosis and sex

266 **Figure 2:** Loss in expectation of life of CML patients in Sweden, over year of

267 diagnosis, by age at diagnosis and sex

268 **Figure 3:** Proportion of expected life lost of CML patients in Sweden, over year of

269 diagnosis, by age at diagnosis and sex.

270

271

272

Figures

Figure 1: Life expectancy of the general population and of CML patients in Sweden,

over year of diagnosis, by age at diagnosis and sex

276

278   **Figure 2:** Loss in expectation of life of CML patients in Sweden, over year of

279   diagnosis, by age at diagnosis and sex

280

Figure 3: Proportion of expected life lost of CML patients in Sweden, over year of

diagnosis, by age at diagnosis and sex

284 **Tables**

285 **Table 1:** Demographic characteristics of CML patients diagnosed in Sweden

286 between 1973 and 2013 at 50 years of age or above

287

	Calendar period								Total	
	1973-1982		1983-1992		1993-2002		2003-2013			
Characteristic	No.	%	No.	%	No.	%	No.	%	No.	%
Total patients with CML	679	25.5	690	25.9	573	21.5	720	27.1	2662	100
Age, years										
50-59	138	20.3	136	19.7	162	28.3	182	25.3	618	23.2
60-69	227	33.4	197	28.6	142	24.8	223	31.0	789	29.6
70-79	214	31.5	240	34.8	179	31.2	180	25.0	813	30.5
>79	100	14.7	119	17.0	90	15.7	135	18.8	442	16.6
Sex										
Male	371	54.6	363	52.6	322	56.2	390	54.2	1446	54.3
Female	308	45.4	327	47.4	251	43.8	330	45.8	1216	45.7

288

Table 2: Life expectancy of the general population (LE), life expectancy of CML patient (LE CML), loss in expectation of life of CML patients (LEL) and proportion of expected life lost of CML patients (PELL) with 95% CIs for males and females at four selected years and four selected ages at diagnosis in Sweden

		Age 55		Age 65		Age 75		Age 85	
		Males	Females	Males	Females	Males	Females	Males	Females
1980	LE	24.3	29.0	15.3	19.3	8.7	11.3	4.5	5.5
	LE CML	3.5 (2.9,4.1)	4.1 (3.4,4.7)	2.7 (2.3,3.0)	3.2 (2.8,3.6)	1.8 (1.5,2.0)	2.2 (1.9,2.4)	0.8 (0.7,1.1)	1.1 (0.9,1.3)
	LEL	20.8 (20.2,21.4)	24.9 (24.3,25.6)	12.6 (12.2,12.9)	16.1 (15.7,16.5)	7.0 (6.7,7.2)	9.1 (8.8,9.4)	3.6 (3.4,3.8)	4.4 (4.2,4.6)
	PELL	0.86 (0.83,0.88)	0.86 (0.84,0.88)	0.83 (0.80,0.85)	0.84 (0.81,0.86)	0.80 (0.77,0.83)	0.81 (0.78,0.83)	0.80 (0.76,0.85)	0.80 (0.76,0.84)
1990	LE	26.3	30.2	16.8	20.5	9.4	12.0	4.8	6.0
	LE CML	5.9 (4.9,7,0)	6.66 (5.6,7.8)	3.8 (3.3,4.3)	4.5 (3.9,5.1)	2.1 (1.8,2.4)	2.6 (2.3,2.9)	0.9 (0.7,1.1)	1.1 (0.9,1.3)
	LEL	20.4 (19.3,21.4)	23.6 (22.4,24.7)	13.0 (12.5,13.5)	16.1 (15.5,16.6)	7.3 (7.0,7.5)	9.4 (9.0,9.7)	3.9 (3.7,4.0)	4.8 (4.6,5.0)
	PELL	0.77 (0.73,0.81)	0.78 (0.74,0.82)	0.77 (0.74,0.80)	0.78 (0.75,0.81)	0.77 (0.75,0.80)	0.78 (0.76,0.81)	0.81 (0.78,0.85)	0.81 (0.78,0.84)
2000	LE	28.2	31.4	18.5	21.7	10.5	13.0	5.0	6.2
	LE CML	15.8 (13.7,17.9)	17.2 (14.8,19.5)	9.3 (8.2,10.4)	10.6 (9.3,11.9)	4.6 (4.0,5.2)	5.5 (4.8,6.3)	1.8 (1.4,2.1)	2.2 (1.8,2.6)
	LEL	12.4 (10.3,14.5)	14.3 (11.9,16.6)	9.2 (8.1,10.3)	11.1 (9.8,12.4)	5.9 (5.3,6.5)	7.4 (6.6,8.2)	3.3 (3.0,3.6)	4.0 (3.6,4.5)
	PELL	0.44 (0.37,0.51)	0.45 (0.38,0.53)	0.50 (0.44,0.56)	0.51 (0.45,0.57)	0.56 (0.51,0.62)	0.57 (0.51,0.63)	0.65 (0.59,0.72)	0.65 (0.58,0.72)
2010	LE	29.9	32.6	20.1	22.8	11.7	14.0	5.7	6.9
	LE CML	27.3 (25.7,28.8)	29.7 (28.0,31.4)	17.5 (16.2,18.9)	19.8 (18.4,21.3)	9.5 (8.5,10.5)	11.3 (10.2,12.5)	4.1 (3.4,4.7)	5.0 (4.2,5.8)
	LEL	2.6 (1.0,4.1)	2.9 (1.2,4.6)	2.5 (1.2,3.8)	2.9 (1.4,4.4)	2.2 (1.2,3.2)	2.6 (1.4,3.8)	1.6 (0.9,2.3)	2.0 (1.2,2.8)
	PELL	0.09 (0.04,0.14)	0.09 (0.04,0.14)	0.13 (0.06,0.20)	0.13 (0.06,0.19)	0.18 (0.10,0.27)	0.19 (0.10,0.27)	0.28 (0.16,0.40)	0.28 (0.17,0.40)